TheraRadar
Data updated: May 26, 2026

MYAMBUTOL (ethambutol hydrochloride)

Infectious Disease Approved 1967-11-06
1
Indication
--
Phase 3 Trials
1
Priority Reviews
58
Years on Market

Details

Status
Discontinued
First Approved
1967-11-06
Routes
ORAL
Dosage Forms
TABLET

Companies

Active Ingredient: ETHAMBUTOL HYDROCHLORIDE

MYAMBUTOL Approval History

1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
136 FDA actions from 1967 to 2013
Feb 2013 SUPPL Priority
Mfg · Manufacturing (CMC)
Oct 2008 SUPPL
Label · Labeling
Mar 2004 SUPPL
Label · Labeling

What MYAMBUTOL Treats

1 FDA approvals

Originally approved for its first indication in 1967 .

  • Other (1)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

MYAMBUTOL FDA Label Details

Track MYAMBUTOL with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.